Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/07/054807
CTRI/2023/07/054807
Not yet recruiting
Phase 3

1. The Role of Androgen Deprivation Therapy In CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1)2. A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2) - RADICAL PC

Dr Jehonathan Pinthus Dr Leong Darryl0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C61- Malignant neoplasm of prostate

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: C61- Malignant neoplasm of prostate
Sponsor
Dr Jehonathan Pinthus Dr Leong Darryl
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Dr Jehonathan Pinthus Dr Leong Darryl

Eligibility Criteria

Inclusion Criteria

  • •Patients with diagnosed prostate cancer who are either
  • •a) Newly diagnosed (i.e. the diagnosis was made within 1 year of the enrolment visit), or
  • •b) Treated with ADT for the first time within 6 months prior to the enrolment visit,
  • •c) To be treated with ADT for the first time within 1 month after the enrolment visit

Exclusion Criteria

  • •Patients will be excluded if they fulfill any of the following:
  • •a) Are unwilling to provide consent, or
  • •b) Are \<45 years of age, or
  • •c) Prostate cancer was found incidentally following cystectomy for bladder cancer
  • •Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
  • •a) See a cardiologist every year, or
  • •b) Both take a statin and have systolic blood pressure \=130mm of Hg

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMetastatic prostate cancerMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004853-26-FITurku University Hospital35
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)
EUCTR2017-002345-29-FITurku University Hospital5
Recruiting
Not Applicable
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.
ACTRN12617001116314St Vincent's Hospital, Sydney20
Active, not recruiting
Phase 4
The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from Chinaprostate cancerCancer - Prostate
ACTRN12613000107729Changhai Hospital, Second Military Medical University100
Recruiting
Not Applicable
Effect of androgen deprivation therapy on uptake of PSMA ligand in patients with salivary duct carcinoma: an explorative study.
NL-OMON48488Radboud Universitair Medisch Centrum14